FIELD: pharmaceutics.
SUBSTANCE: present invention relates to a pharmaceutical composition in form of a tablet containing a) therapeutically effective amount of sodium salt (4-{4-[5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid, b) sodium lauryl sulphate as a surfactant with properties of lubricant substance in amount of 0.1 to 5 %, c) low-substituted hydroxypropyl cellulose in dry binder with properties of baking powder in amount of 2 to 20 %, d) mixture of microcrystalline cellulose and anhydrous lactose as filler in ratio of 1:5 to 1:1 and e) sodium starch glycolate as a disintegrant in amount of 1 to 10 % by weight of tablet before application of film coating. Invention also relates to a method of preparing a pharmaceutical composition and use thereof as a medicinal agent.
EFFECT: compositions demonstrate compression profile with a wide hardness window, which provides acceptable brittleness, hardness, decomposition and dissolution time and sufficient stability to achieve rational storage life.
10 cl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
LENALIDOMIDE TABLET COMPOSITION FOR ORAL ADMINISTRATION | 2017 |
|
RU2725074C1 |
TABLET OF MELATONIN AND METHOD FOR PREPARING AND USING | 2008 |
|
RU2485949C2 |
NEW COMPOSITION OF LAPATINIB AS A SOLID DOSAGE FORM FOR ORAL USE AND A METHOD OF ITS MANUFACTURE | 2019 |
|
RU2821950C2 |
DRY GRANULATION PROCESS FOR PRODUCING TABLET COMPOSITIONS OF METFORMIN AND COMPOSITIONS THEREOF | 2013 |
|
RU2647421C2 |
SOLID DOSAGE FORMS OF PALLBOCYCLOB | 2016 |
|
RU2686840C1 |
COMPOSITIONS IN FIXED DOSES | 2018 |
|
RU2810163C2 |
TABLETS AND GRANULATED POWDERS CONTAINING 6-FLUOR-3-HYDROXY-2-PYRAZINCARBOXAMIDE | 2010 |
|
RU2527766C2 |
IRBESARTAN-CONTAINING PHARMACEUTICAL COMPOSITIONS | 2008 |
|
RU2465900C2 |
DOSAGE FORM WITH IMPROVED CHARACTERISTICS OF pH-DEPENDENT RELEASE OF PREPARATION CONTAINING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2017 |
|
RU2716025C1 |
CORTICOSTEROID-CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR TREATING EOSINOPHILIC ESOPHAGITIS | 2014 |
|
RU2678695C2 |
Authors
Dates
2016-08-27—Published
2011-10-14—Filed